What is Nureca Ltd (NURECA) share price return in the past 10 years?

Data is not available for this company

What is the share price of Nureca Ltd (NURECA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Nureca Ltd (NURECA) on 22-Sep-2026 13:27:00 at 13:27 is 333.65.

What is the P/E ratio of Nureca?

The latest standalone P/E ratio of Nureca as of 22-Sep-2026 is 148.56.

What is the P/B ratio of Nureca Ltd (NURECA)?

The latest standalone P/B ratio of Nureca Ltd (NURECA) as of 22-Sep-2026 is 1.80.

What is the 52-week high and low of Nureca Ltd (NURECA)?

The 52-week high of Nureca Ltd (NURECA) is Rs. 358.00 and the 52-week low is Rs. 200.10.

Nureca Ltd (NURECA)

Name: Nureca Ltd (NURECA)
Brand: Nureca

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543264 NSE: NURECA Medical Equipment/Supplies/Accessories | Small Cap | Nureca Share Price

₹333.65 -5.45 (-1.61%)

As on 22-Sep'26 13:27

Nureca Ltd (NURECA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543264 NSE: NURECA Medical Equipment/Supplies/Accessories | Small Cap | Nureca Share Price

₹333.65 -5.45 (-1.61%)

As on 22-Sep'26 13:27

Key Metrics

Valuation Multiples

Market Cap

₹324 Cr.

Current Price

₹333.7

52-Week Low / High

₹200 / 358

TTM EPS

₹4.6

TTM Sales

₹153 Cr.

Book Value per Share

₹192.7

P/E Ratio

74.61

Industry PE

127.5

Price to Book (P/B)

1.76

In line with its 5-year historical median

Price to Sales (P/S)

2.11

Lower than its 5-year historical median

EV/EBITDA

24.58

Higher than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

1.11%

Underperforms industry median

Return on Capital Employed (ROCE)

3.31%

Underperforms industry median

Return on Assets (ROA)

1.04%

Operating Profit Margin

5.8%

Net Profit Margin

1.42%

Gross Profit Margin

4.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

28.41%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

144.71%

Asset Quality

Promoter Holding

68.09%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹174 Cr.

Equity

₹9.5 Cr.

Face Value

₹10

All Time Low / High

₹198.00 / 2316.60

Nureca stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Somewhat Undervalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Nureca Ltd a good quality company?

Nureca Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Nureca Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Nureca Ltd vs industry peers?

Nureca Ltd revenue CAGR is -7.19%, compared to the industry median CAGR of 0.00%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Nureca Ltd?

Promoters hold 68.09% of the Nureca Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Nureca Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -26.99% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	0%	103.9%	92.4%	76%	67.7%	33.6%	-5.3%	-1.5%	0.3%	2.1%	-
Value Creation Index ⓘ	NA	6.4	5.6	4.4	3.8	1.4	-1.4	-1.1	-1.0	-0.9	-
Growth Parameters ⓘ
Sales ⓘ	0	0.6	0.7	99.4	213	256	112	94.5	115	147	153
Sales YoY Gr.	-	NA	23.7%	13,520.6%	114.6%	19.8%	-56.2%	-15.5%	21.3%	28.4%	-
Adj EPS ⓘ	0	2.2	2.8	911.6	46.6	44.7	-10.1	-2.8	-0.8	5.6	2.3
YoY Gr.	-	NA	26.5%	32226.6%	-94.9%	-4.1%	-122.5%	NA	NA	NA	-
BVPS (₹) ⓘ	0	3.3	6.4	1,995.7	163.3	203.7	195.3	192.9	192.5	185.7	188.2
Adj Net Profit ⓘ	0	0	0	6.4	46.6	44.7	-10.1	-2.8	-0.8	5.4	2
Cash Flow from Ops. ⓘ	0	0	0.1	-7.9	35.1	1.8	12.1	-3	-18.8	0.3	-
Debt/CF from Ops. ⓘ	0	0	0	-1.2	0	0.6	0	-0.1	-0.1	2.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	-7.2%	9.6%	28.4%
Adj EPS ⓘ	NA	-34.5%	NA	NA
BVPSⓘ	NA	2.6%	-1.7%	-3.5%
Share Price	-	-27.2%	-1%	39.3%

Key Financial Parameters ⓘ

	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	60.4	54.4	85	52.3	24.4	-5.1	-1.4	-0.4	2.9	1.2
Op. Profit Mgn % ⓘ	4	4.2	9.8	29.4	22.1	-13.5	-11.8	-8.5	3.9	0.6
Net Profit Mgn % ⓘ	2.7	2.7	6.4	21.9	17.5	-9	-2.9	-0.7	3.7	1.4
Debt to Equity ⓘ	0	0	0.7	0	0	0	0	0	0	-
Working Cap Days ⓘ	0	360	60	83	130	291	204	166	227	177
Cash Conv. Cycle ⓘ	0	104	39	38	58	141	101	86	94	159

Valuation of Nureca - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	20	62	99	213	256	111	92	110	147
Operating Expenses ⓘ +	16	53	90	152	200	126	102	117	147
Manufacturing Costs	0	0	0	14	2	1	1	1	1
Material Costs	11	40	65	99	133	76	61	68	93
Employee Cost	0	1	3	5	10	16	12	15	17
Other Costs ⓘ	4	12	22	34	56	34	29	33	36
Operating Profit ⓘ	4	9	10	62	56	-15	-10	-8	0
Operating Profit Margin (%)	21.8%	14.6%	9.7%	28.8%	21.7%	-13.5%	-11.1%	-7.1%	0.1%
Other Income ⓘ +	0	0	0	3	8	7	11	13	8
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	1	2	1	0	0	1	1
Depreciation ⓘ	0	0	0	0	1	2	2	2	2
Profit Before Tax ⓘ	4	9	9	62	61	-11	-3	1	5
Tax ⓘ	1	3	2	16	16	-2	-1	0	3
Profit After Tax	3	6	6	46	45	-8	-2	1	2
PAT Margin (%)	15.5%	10.1%	6.4%	21.7%	17.6%	-7.4%	-2.0%	0.8%	1.4%
Adjusted EPS (₹)	444.6	889.4	913.6	46.4	45.0	-8.3	-1.8	0.9	2.2
Dividend Payout Ratio (%)	0%	0%	0%	4.30%	6.70%	0%	0%	0%	0%

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	1	7	14	163	203	195	193	194	181
Share Capital ⓘ	0	0	0	10	10	10	10	10	10
Reserves ⓘ	1	7	14	153	193	185	183	184	171
Debt +	0	0	9	1	0	0	0	2	0
Long Term Debt	0	0	9	1	0	0	0	1	0
Short Term Debt	0	0	0	0	0	0	0	1	0
Minority Interest	0	0	0	0	0	0	0	0	0
Trade Payables	5	10	6	9	5	5	5	7	5
Others Liabilities ⓘ	1	7	5	17	44	4	2	4	8
Total Liabilities ⓘ	7	24	34	190	252	204	200	207	194
Fixed Assets
Net Fixed Assets ⓘ +	0	1	1	4	10	9	7	9	14
Gross Block	0	1	1	4	12	11	10	14	21
Accumulated Depreciation	0	0	0	0	2	2	3	5	7
CWIP ⓘ	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	33	59	94	1	1
Inventories	4	14	16	37	63	34	31	40	48
Trade Receivables	2	9	13	0	3	4	2	3	8
Cash Equivalents ⓘ	0	0	0	127	84	71	45	127	41
Others Assets ⓘ	2	0	3	23	58	26	21	26	82
Total Assets ⓘ	7	24	34	190	252	204	200	207	194

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	0	0	-8	35	1	10	-3	-19	3
PBT ⓘ	4	9	9	62	61	-11	-3	1	5
Adjustment ⓘ	0	0	1	0	-4	-3	-7	-9	5
Changes in Working Capital ⓘ	-4	-9	-18	-13	-38	29	5	-10	-7
Tax Paid ⓘ	0	-0	-0	-15	-18	-4	1	-1	0
Cash Flow From Investing Activity ⓘ +	-0	-0	-0	-110	-3	-16	18	8	14
Capex	-0	-0	-0	-1	-6	-0	-1	-4	-6
Net Investments	0	0	0	-109	-1	-17	9	5	15
Others ⓘ	0	0	0	0	4	1	10	8	6
Cash Flow From Financing Activity ⓘ +	-0	-0	8	92	-7	-2	-1	-0	-20
Net Proceeds from Shares ⓘ	0	0	0	105	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0	0	-1	-8	-1	0	0	1	-1
Interest Paid ⓘ	-0	-0	-1	-1	-0	-0	-0	-1	-1
Dividend Paid ⓘ	0	0	0	0	-5	0	0	0	0
Others ⓘ	0	-0	10	-4	-1	-1	-1	-0	-17
Net Cash Flow ⓘ	0	0	-0	17	-9	-8	14	-11	-2

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	426.3	162.03	61.23	52.39	24.55	-4.14	-0.92	0.44	1.11
ROCE (%)	255.06	179.97	56.7	67.61	33.57	-5.17	-1.06	1.31	3.31
Asset Turnover Ratio	2.86	4.18	3.61	2.01	1.22	0.51	0.49	0.6	0.8
PAT to CFO Conversion(x)	0	0	-1.33	0.76	0.02	N/A	N/A	-19	1.5
Working Capital Days
Receivable Days	30.70	30.20	38.40	10.60	2.10	11.30	10.80	7.40	12.70
Inventory Days	64.40	48.90	52.90	43.20	67.50	152.90	119.30	105.90	100.30
Payable Days	173	68.30	44	26.70	18.50	23.50	30.60	31.50	22.90

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Nureca Ltd FAQs

The current trading price of Nureca on 22-Sep-2026 13:27 is ₹333.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Nureca stood at ₹323.6 Cr

The latest P/E ratio of Nureca as of 21-Sep-2026 is 148.6.

The latest P/B ratio of Nureca as of 21-Sep-2026 is 1.80.

The 52-week high of Nureca is ₹358.0 and the 52-week low is ₹200.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nureca is ₹153 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nureca Ltd is a average quality company.

The key valuation ratios of Nureca Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Nureca Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Nureca Ltd

Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website drtrust.in.

The company has most of the product lines supporting home health market in India, making it a one-stop solution provider. Dr Trust is a known for its innovative products in the market, and, with the segment showing significant potential for growth, the company is positioned to show significant growth.

The company has a diversified product portfolio, which primarily caters to home healthcare sector. It provides an improved product mix to its customers and their preferences thereby targeting a wider customer base. Its growth is further driven by its ability to make available an assortment of quality products under trusted brands built by the company.

Products:

Currently, the company classify its products portfolio under the following five categories such as:

Chronic Device Products - which includes products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self monitoring glucose devices, humidifier and steamers.
Orthopedic Products - which includes rehabilitation products such as wheelchairs, walkers, lumbar and tailbone supports and physiotherapy electric massagers.
Mother and Child Products - which includes products such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carry cots.
Nutrition Supplements - which includes products such as fish oil, multivitamins, probiotics, botin, apple cider and vinegar.
Lifestyle Products - which includes products such as smart scales, aroma diffusers and fitness tracker.

Key awards, recognitions and accreditations

2020: The company received ISO 9001:2015 Certificate of Registration from Intertek Certification Limited for Management System, which is applicable to sales, services and warehousing of medical devices, consumer electronics, pharmaceutical and personal care products.
2020: Appreciation Letter from Pharmaceuticals Export Promoter Council of India stating the company as a very dynamic and evolving medical devices company and has created a credible and leading brand ‘Dr. Trust’ which is now a household name in India.

Major events and milestones:

2016: Online launch of Dr. Trust Brand.
2017: Launched Dr. Physio brand in electric massager categories and Trumom brand in mother and child care categories.
2017: Started three flex centres in Punjab, Karnataka and Uttar Pradesh.
2018: The company became the wholly owned subsidiary of Nectar Biopharma Private Limited.
2018: Added three flex centres in Chandigarh, Telangana and Maharashtra.
2018: Secured warehouse drug license.
2020 Transfer and vesting of Specified Undertaking (as defined under the Scheme) from Nectar Biopharma Private Limited to the company pursuant to the Scheme of Arrangement.

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Nureca Ltd (NURECA)

Nureca Ltd (NURECA)

Nureca stock performance